Risk-share pays off for Lilly as it takes back migraine antibody
This article was originally published in Scrip
Executive Summary
Eli Lilly is acquiring all rights to a therapeutic migraine antibody that it discovered and then licensed to new company Arteaus Therapeutics for development in 2011.
You may also be interested in...
Finance Watch: Arteaus Comes Full Circle As Investors Monetize Emgality Royalties
Arteaus sells royalty stream from Lilly's Emgality giving investors a $260m payday. Also, Pfizer spin-out SpringWorks nabs another $125m, Arch Oncology and Prevail Therapeutics close $50m Series B rounds, and Karuna's recent financing grows to $80m.
Best-In-Class Or First-In-Class: CGRP Inhibitors Line Up To Win The Migraine Market
Amgen will be the first biopharma company to seek approval for a CGRP inhibitor when it submits a BLA for FDA approval later in the second quarter, but Alder, Lilly, Teva and Allergan are in the running for best-in-class status to treat unmet needs in migraine and other headache markets.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.